Clinical trials: Liver Cell Carcinoma Non-resectable, open to volunteers
Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
- Trial name
- FAD-HCC-001 (NCT07314372)
- Testing
- Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatocellular Carcinoma Non-resectable
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable…
- Trial name
- ExTRACT-HCC (NCT04965454)
- Testing
- Fluorine-18 fluorocholine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Queen's Medical Center
HCC
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma
Although the combination of transarterial chemoembolization (TACE) with PD-1 inhibitor plus lenvatinib has become a new standard, the therapeutic efficacy for unresectable hepatocellular carcinoma (uHCC) still requires…
- Trial name
- NCT07340502
- Testing
- TACE, HAIC, PD-1inhibitors
- Volunteers
- 364 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy
- Trial name
- NCT06244225
- Testing
- Donafenib； Sintilimab； HAIC
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (DST) to guide…
- Trial name
- NCT07351513
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 94 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma Non-resectable
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC).
- Trial name
- NCT05985798
- Testing
- Sin-Bev-TACE, Len-TACE
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Liver Neoplasms
TheraSphere Japan Pre-Market Study
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
- Trial name
- INDIGO (NCT07377487)
- Testing
- TheraSphere Y-90 glass microsphere
- Where
- 5 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
HCC - Hepatocellular Carcinoma
The DoHAICs Study Expansion Phase
We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
- Trial name
- NCT07584018
- Testing
- Donafenib, sintilimab, HAIC
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
- Trial name
- NCT07543510
- Testing
- TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients…
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03942328
- Testing
- Atezolizumab, Bevacizumab, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07209813
- Testing
- GKL-006 Injection, TACE
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Unresectable Hepatocellular Carcinoma
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as…
- Trial name
- NCT06360042
- Testing
- Adebrelimab plus Apatinib, Adebrelimab plus Bevacizumab, Camrelizumab plus Apatinib
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Peking University Cancer Hospital & Institute
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Transarterial Chemoembolization
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery.
- Trial name
- NCT07281664
- Testing
- Transarterial chemoembolization (TACE), bevacizumab and atezolizumab
- Volunteers
- 30 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the treatment of unresectable hepatocellular carcinoma.
- Trial name
- NCT05409482
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Meng Chao Hepatobiliary Hospital of Fujian Medical University
Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma.
- Trial name
- NCT07391839
- Testing
- MDN-001 Injection(Yttrium-90 Microsphere Injection)
- Where
- 8 sites in China
- Volunteers
- 40 people
- Sponsor
- Suzhou Mednovo Yi Medical Technology Co., Ltd.
Unresectable Hepatocellular Carcinoma
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.
- Trial name
- ABH-uHCC (NCT07806292)
- Testing
- anlotinib combined with benmelstobart and HAIC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HCC - Hepatocellular Carcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
This study is a multicenter retrospective clinical research, led by the First Affiliated Hospital of Wenzhou Medical University, and jointly conducted by other sub-centers.
- Trial name
- NCT07495735
- Testing
- No intervention (observational study)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University